New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Stuffing. And all the appetizers. The holidays usually mean indulging in your favorite treats — but Thanksgiving may look very different if you’re on an injectable GLP-1 weight-loss medication such as ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Wegovy's approval by China's NMPA targets individuals with a BMI of 30+ with related health issues; initial supply will be ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...